pharmaceutical discussion group
TRANSCRIPT
-
7/28/2019 Pharmaceutical Discussion Group
1/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Pharmaceutical Discussion Group
Long term staility studies output handling
Mohammed Zghoul
Sat, Dec 11, 2010 5:15 PM
Dear all;
the relation between assay,dissolution,Related substances and even physical test results and test
intervals e.g. 3,6,9,12,18,24,36...
are concidered as a time seriese in statistics.
there is a differance whene we compare the results of 3 Vs 6 and 24 Vs 36
while there is a 3 months to 12 months period
so we cant say the drop dow from interval to another should not exceed 5%
it maybe like this 3 to 6 +/-3% with tolerance and from 12 to 18 4% with tolerance and so on.
the question is how can i deside that a result at an interval in the study for a certain Batch/product.
should be investegated there something wrong with it inspite of being withen shelf life limits?
assay of a product:
initial 3 6 9 12 18 24 36 48 60
101.1 99.1 98.3 96.0 94.0 95.5 94.5 97.1 91.3 92.1
limit: (90-110)%
regards
Mohammed
Reply to Topic
Replies to this Topic
Show
Marc Gordon
Sun, Dec 12, 2010 12:47 AM
Actions
-
7/28/2019 Pharmaceutical Discussion Group
2/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Dear Mohammed,
Regarding your question, my thought is that guidelines indicate that the key is to always compare a time
point back to the initial value. For example, the "ICH HARMONISED TRIPARTITE GUIDELINE STABILITY
TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS Q1A(R2)" states the following:
"If long-term studies are conducted at 25C 2C/60% RH 5% RH and significant
change occurs at any time during 6 months testing at the accelerated storage
condition, additional testing at the intermediate storage condition should be
conducted and evaluated against significant change criteria. The initial application
should include a minimum of 6 months data from a 12-month study at the
intermediate storage condition.
In general, significant change for a drug product is defined as:
1. A 5% change in assay from its initial value; or failure to meet the acceptance
criteria for potency when using biological or immunological procedures;
2. Any degradation products exceeding its acceptance criterion;
3. Failure to meet the acceptance criteria for appearance, physical attributes, and
functionality test (e.g., color, phase separation, resuspendibility, caking,
hardness, dose delivery per actuation); however, some changes in physical
attributes (e.g., softening of suppositories, melting of creams) may be expected
under accelerated conditions;
and, as appropriate for the dosage form:
4. Failure to meet the acceptance criterion for pH; or
5. Failure to meet the acceptance criteria for dissolution for 12 dosage units. "
Note that in item 1 it specifies from its initial value, not from an intermediate time point to a later time
point. Therefore, if the Total Content changed from T=0 being 100%, to T=3 months being 96%, and T=6
months being 92%, even though the change between time points never exceeded 5%, since the total at
6 months compared to the initial value was greater than 5%, it is a "significant change.
-
7/28/2019 Pharmaceutical Discussion Group
3/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Marc
Reply to Topic
Permalink
Mohammed Zghoul
Sun, Dec 12, 2010 1:31 PM
Actions
Dear Mr. Gorden;
what about the acceptance cretiria (90-110)% in some cases and (50-120)% for presirvative in some
cases the 5% is impossible to reach, how we can conduct the acceptable drop down to the acceptance
cretiria if the product meets all acceptance cretiria concerning impurities, related
substances,assay,Dissolution and physical test?
the comparison between any test point with the initial point to not exceed 5% change from 0 to 60 then
there is an acceptable drop down from interval to the next one as below by applying liniarity:
test point 0 3 6 9 12 18 24 36 48 60
result 100.00 099.75 099.50 099.25 099.00 098.50 098.00 097.00 096.00 095.00
drop down 0 0.25 0.25 0.25 0.25 0.5 0.5 1 1 1
why do we make it (5%) while acceptance cretiria varies from product to another?
i think that the 5% is in case of (95-105)%! but in case of 90-110 or 80-120 what it should be?
Reply to Topic
Permalink
Marc Gordon
Mon, Dec 13, 2010 11:08 PM
Actions
-
7/28/2019 Pharmaceutical Discussion Group
4/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Dear Mohammed,
Acceptance Criteria and ICH "significant change" are two separate items. If you fail your assay
acceptance criteria, that is usually a shelf-life limiting event. However, you can have a significant change
and still continue with your stability program and have a longer shelf life, as long as you still meet your
Acceptance Criteria and can explain why the significant change should not shorten your shelf. I have
had significant changes that were within the Acceptance Criteria limits, and I justified the significant
change due to assay variability limitations, and the FDA accepted the justifications. Regarding another
aspect of your queries, if the Acceptance Criteria are tighter than the significant change criteria, then
significant change becomes irrelevant and only your Acceptance Criteria matter.
You also appear to be mixing up the criteria for different tests. The 5% significant change only applies to
assay values, while degradation limits are based on a separate ICH requirement, and dissolution is based
yet a different set of parameters. You need to be familiar with the specific sections of the guidelines
that pertain to the different tests. I recommend that you carefully read the entire set of ICH guidelines.
It will take some time, but you find it very helpful.
Marc
Reply to Topic
Permalink
Marc Gordon
Mon, Dec 13, 2010 11:16 PM
Actions
Dear Mohammed,
As I hit the reply button, I realized that I should have specified when I wrote "If you fail your assay
acceptance criteria, that is usually a shelf-life limiting event" by adding " at that storage condition." You
can, of course, usually drop down to test results at a lower temperature/RH storage condition to justify
a longer shelf life but with limitations on the storage conditions.
-
7/28/2019 Pharmaceutical Discussion Group
5/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Marc
Reply to Topic
Permalink
Mohammed Zghoul
Tue, Dec 14, 2010 3:03 PM
Actions
Dear Mr. Gorden;
thank you for your answers.
i want to ask you about the delay time allowed between the manufacturing date and incubation date
the maximum delay time and the period of time allowed for studying a sample since we withdraw it
from the climatic chamber for long term stability?
thank you
Best regards
Mohammed
Reply to Topic
Permalink
Marc Gordon
Wed, Dec 15, 2010 12:01 AM
Actions
-
7/28/2019 Pharmaceutical Discussion Group
6/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Dear Mohammed,
From a regulatory point of view, I don't know that there is a set maximum allowable period between the
manufacturing date and the set up date in a stability chamber. However, if this interval exceeds 30 days
(I have seen other periods used as well), it is good practice to mandate in your SOPs that the product will
be completely retested, and the new set of release tests will become the T=0 stability data. Then the
driver to get the lot's stability set up completed in a timely fashion becomes the desire to avoid the time
and expense of retesting, and the fact that you may be shortening your shelf life since the lot that is set-
up on stability has undergone some period of aging before your stability test starts, but from a shelf life
perspective the aged material is treated as if it was freshly prepared.
The companies that I am familiar with have often used a period of around 30 days as the maximum
delay time between when a sample is pulled from a stability chamber and when it must be tested by.
This interval is somewhat company dependent, and should be specified in your company's SOPs (you
should add it to your SOPs if it is not there now).
Regards,
Marc Gordon
Reply to Topic
Permalink
raymond maikokera
Wed, Dec 15, 2010 12:08 PM
Actions
Dear Gordon
I am interested in the maximum allowable period between
-
7/28/2019 Pharmaceutical Discussion Group
7/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
1. manufacturing date and the set up date in a stability chamber
2. maximum delay time between when a sample is pulled from stability chamber and when it must be
tested
you said the period is company dependent and some goes up to 30 days.
Does it mean that there is no set period in ICH guidelines?
we use +/- 3days for accelerated stability and +/-7 days for long term stability studies but I do not know
where these time frames come from.
On a different stability issue; after statistical analysis of stability data, I found that most of the p-values
for the quantitative parameters are below 0.25 although they all meet the acceptance criteria. How do I
discus the data in the results analysis report?
regards,
Raymond Maikokera
Reply to Topic
Permalink
PRASAD BEDKIHAL
Fri, Dec 17, 2010 7:40 PM
Actions
Dear All,
-
7/28/2019 Pharmaceutical Discussion Group
8/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
In this case as Raymod mentioned the maximum allowable time frame for completion of analysis, is
there any time period for withdrawal of the samples from Stability chambers? This is practical situation
where it is not always possible to pull the samples from chambers on the exact period.
Regds
Prasad
Reply to Topic
Permalink
siva prasad mylapuri
Sun, Jun 5, 2011 4:58 PM
Actions
Dear all,
what ever Mr.Raymond Maikokera said,we are also follwing the same in my organisation.But i to dont
know which guideline it said like that.As per my knowledge it is a logical thing.For accelarated testing
there is very less due (+/- 3 days) is there because, in accelated studies we are using higher temp and
humidity condition,so if due period is more degradation will increase,in long term we are using the
actual drug storage condition,if due time more also it may not effect more,so as per logic it may be
fixed.
-
7/28/2019 Pharmaceutical Discussion Group
9/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
Regards
Siva prasadarao mylapuri
Reply to Topic
Permalink
raymond maikokera
Fri, Sep 16, 2011 2:46 PM
Actions
Hi all
may someone help me or refer me to an article where i can have thorough understanding of statistical
analysis of stability data, like after 6 months accelerated and at long term. how does one comment on
the p-values below 0.25 for certain parameters which still meet the acceptance criteria?
Regards
Raymond
Reply to Topic
Permalink
Post Reply
You must be logged in and a member of this Groupsite in order to post a reply to this topic.
-
7/28/2019 Pharmaceutical Discussion Group
10/10
http://phdig.groupsite.com/beta/discussion/topics/434092/messages
To post a reply, contact your group manager(s) Join this Groupsite
RSS Feed for this Topic
Go
Advertisement
Feedback
FAQs
Video Tour
Terms of Service
Privacy Policy
Status
Content 2013 Pharmaceutical Discussion Group. All Rights Reserved.
Groupsite.com